Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine
- 1 January 1992
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 22 (6) , 721-730
- https://doi.org/10.3109/00498259209053134
Abstract
1. Four volunteers phenotyped as extensive metabolizers of sparteine took 25 mg nortriptyline hydrochloride and collected urine for 72-80 h. Total free and conjugated 10-hydroxynortriptyline (10-OH-NT) accounted for 54-58% of the dose and it was reduced to 25-40% when 50 mg quinidine sulphate was ingested on the first and second day. 2. Of the four isomers of 10-OH-NT, (-)-E-10-OH-NT was selectively decreased in quantity by quinidine coadministration, while the (+)-isomer and (-)- and (+)-Z-10-OH-NT were found in unchanged or slightly increased quantities. The contribution of (-)-E-10-OH-NT to total E-10-OH-NT and the E-/Z-ratio in total 10-OH-NT were significantly reduced. 3. The quantity of the phenol, 2-hydroxynortriptyline in urine was decreased by quinidine; the relative amounts of metabolites with a primary amino group were not affected. 4. Liver microsomes from a donor in which cytochrome P450IID6 was shown to be present by in vitro phenotyping metabolized NT to E-10-OH-NT containing 86% of the (-)-isomer. Quinidine reduced the hydroxylation rate in (-)-E-10-position much more than that in (+)-E-10-position. 5. Since quinidine selectively impairs the function of cytochrome P450IID6, it is concluded that this isoform catalyses NT hydroxylation predominantly in (-)-E-10- and in 2-position.Keywords
This publication has 12 references indexed in Scilit:
- Enantioselective Hydroxylation of Nortriptyline in Human Liver Microsomes, Intestinal Homogenate, and Patients Treated with NortriptylineTherapeutic Drug Monitoring, 1991
- A dose‐effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.British Journal of Clinical Pharmacology, 1990
- Steady-State Plasma Levels of E- and Z-10-OH-Nortriptyline in Nortriptyline-Treated PatientsTherapeutic Drug Monitoring, 1989
- Pharmacogenetics of AntidepressantsPublished by Springer Nature ,1989
- Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.British Journal of Clinical Pharmacology, 1988
- Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.Published by Wiley ,1986
- A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liverLife Sciences, 1986
- The genetic polymorphism of sparteine metabolismXenobiotica, 1986
- Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparationsXenobiotica, 1986
- [22] The measurement of difference spectra: Application to the cytochromes of microsomesPublished by Elsevier ,1978